Does the Spark Therapeutics writedown undermine Philly's biotech swagger? Startups have bigger things to worry about, they say

A shining star of Philadelphia's life sciences ecosystem recently faced a setback, putting a dent in the region's reputation for success in the sector.
Cell and gene therapy standout Spark Therapeutics is being restructured following the end of its trial for a hemophilia A gene therapy treatment, and parent company Roche is classifying the former startup as a financial loss, according to the Philadelphia Inquirer.
Spark says it's still working on a new gene product for the disease and stakeholders say this downturn doesn't discredit its years of impact. The situation is, however, calling attention to how life sciences startups face challenges like federal funding cuts and product development costs — though industry leaders still say they're optimistic about staying afloat by tapping into the talent and resources that exist here.
One restructuring setback won't worsen investment opportunities for other life science ventures, according to Dean Miller, president of the Philadelphia Alliance for Capital and Technologies.
'You're not going to dissuade investors because a pharmaceutical company deprioritized an acquisition,' Miller said. 'That happens all the time.'
Philadelphia is consistently a top region for venture capital and life sciences. The Philadelphia Metropolitan Statistical Area is a top-five venture capital market in the US, with life sciences as one of its major sectors, according to PitchBook's quarterly Venture Monitor report.
Despite the high ranking, access to capital remains one of Philly's top challenges, especially locally, per Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce.
Recent challenges like Spark's signal that the industry needs to work toward making gene therapy manufacturing more cost effective, which would get more therapies to market and help attract investment, Grant told Technical.ly. But it's also an example of how a company can pivot to stay afloat and continue working.
'They really created a lot of recognition for gene therapy and innovation,' Grant said. 'Now more people understand what gene therapy means and how it can literally cure disease.'
Spark Therapeutics did not immediately respond to Technical.ly's request for comment.
Spark signaled strength in Philly life sciences — what does it mean now?
Spark Therapeutics is one of Philly's go-to examples of success, and it helped build up the ecosystem in Philadelphia, Miller said. While restructuring could lead to staff cuts or shrinking offices, following layoffs at the company last summer, this is likely a short-term pain point, he said.
After developing the first FDA-approved gene therapy, Luxturna, the Penn spinout broke into the mainstream. When pharma giant Roche acquired Spark in 2019, it was the largest VC-backed exit in Philadelphia at $4.8 billion, bringing more attention to Philly's life sciences ecosystem.
'[It's] never easy when your trailblazer starts to disappear a little further.'
Dean Miller, president of the Philadelphia Alliance for Capital and TechnologieS
Since then, the company welcomed a new CEO and announced plans for its 500,000 square foot Gene Therapy Innovation Center in University City, which is expected to be completed next year. The company previously said the site would house over 500 jobs.
'Gene therapy is not a huge sector, and Spark was a trailblazer,' Miller said. '[It's] never easy when your trailblazer starts to disappear a little further.'
Still, stories like Spark's are something that the ecosystem has seen before. Big successes come and go, but the momentum remains, he said, pointing to the example of Centocor, a biotech company founded in Philadelphia in 1979.
Centocor's work was groundbreaking at the time, developing large molecule therapies and treatments for rheumatoid arthritis, Crohn's disease and other medical conditions, Miller said.
Johnson and Johnson acquired Centocor in 1999 for $4.9 billion. At the time of acquisition, Centocor maintained its brand identity, but eventually completely integrated into Johnson and Johnson. However, the people who worked at Centocor are still around in the Philly life sciences ecosystem and helping new biotech startups get off the ground, Miller said.
'Twenty years from now, I think we'll be saying the same thing about Spark and its impact,' Miller said. 'Not just what it did in developing a new line and approach to gene therapy, but how its people went on to found other companies, to fund other companies.'
Fed funding blocks, fleeing investors are the bigger rift
Current economic uncertainty and funding changes at the federal level do signal a bit more concern around Spark's turmoil, Miller said.
The Trump Administration recently proposed huge cuts to funding for the National Institutes of Health, already seeing grants for vaccine-hesitancy research being rescinded. Philadelphia received $5.9 billion from the NIH between 2019 and 2023, according to the Commerce Department's 2024 Life Sciences Impact Report.
Without NIH funding, the United States will fall behind in terms of medical research, Grant said. While stakeholders hold out hope that the administration will change course, the ecosystem needs to start thinking about alternative funding opportunities, like philanthropic foundations and a local pilot program that Grant said the city is working on to target early-stage life sciences companies through the city's small business catalyst fund.
'It takes millions and millions of pre-revenue dollars to bring a drug to market,' Grant said. 'So I'm developing and thinking out a program that I hope to release soon that can help small companies around the city that are moving towards commercialization.'
However, this uncertainty could offer a benefit for Philly, she said. If there are fewer funding opportunities and companies have to be more careful with money, Philadelphia's affordability could attract more companies.
This could also be an opportunity to increase collaboration across the ecosystem and make capital stretch farther, she said. Researchers doing similar work at different institutions may choose to team up and have a better shot at funding while they wait for more VCs to come through with cash.
'We would always love to see some bigger, deeper-pocketed investors,' said Kathie Jordan, managing director of the healthcare investment group at Ben Franklin Technology Partners of Southeastern Pennsylvania, 'and we continue to work on building out those relationships with investors who really can lead those rounds in the tens of millions.'
Philly leans on new labs, strong workforce to push ahead
Despite setbacks, Philadelphia continues to lean into its strengths and work toward growing the life sciences ecosystem.
Lab and office space is a huge opportunity in the region right now, Grant from the Commerce Department said. Developers are continuing to build more workspace and companies are showing interest in these spaces even before they're finished.
'I don't think people would be continuing to invest if they felt like this ecosystem was going to fail,' she said.
'I don't think people would be continuing to invest if they felt like this ecosystem was going to fail.'
Rebecca Grant, senior director of life sciences and innovation for Philly's Department of Commerce
The city also has a strong talent pool and workforce, she said. The region ranked No. 8 for life sciences talent on CBRE's 2024 US Life Sciences Talent Trends report, slipping down two spots, but remaining in the top 10 for the third year in a row. The lower cost of living and proximity of major research institutions are also benefits.
New success stories are also coming up. For example, Mineralys Therapeutics stock price surged after announcing positive clinical trial results for its hypertension drug candidate lorundrostat. The company raised $192 million after going public last year.
As companies like Mineralys continue to grow, they will also hire the talent that exists here in the market, Miller said.
But Philly needs to learn how to market itself better and get comfortable touting its accomplishments, Grant said. The key is to 'evangelize' everything the ecosystem has to offer.
'We've always maintained our head above water,' Grant said. 'The innovation we're creating here is just so important to the greater good globally. We'll continue to innovate.'
Sarah Huffman is a 2022-2024 corps member for Report for America, an initiative of The Groundtruth Project that pairs young journalists with local newsrooms. This position is supported by the Lenfest Institute for Journalism.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Technical.ly

12-06-2025

• Technical.ly

Philly is now one of the top 15 places in the world to launch a startup

Philadelphia jumped 12 spots in a national ranking of startup ecosystems, placing the city among the top 15 places in the world to found a company. The region is now ranked No. 13 in the 2025 Global Startup Ecosystem Report from trade association and research group Startup Genome and the Global Entrepreneurship Network. Over the last five years, Philly has climbed 35 spots, the report states — a sign that collaboration in the innovation scene is working, said Tiffany Wilson, president and CEO of the University City Science Center, a Startup Genome member. 'We've been laying groundwork … over the last few years, and starting to see some early indications of companies seeing success as a result,' Wilson told 'It's the right activity at the right time.' Last year, Philly broke the top 25, an improvement over the previous year when the city ranked No. 27. The latest ranking can be partially attributed to the billions of dollars flowing into the scene. Philadelphia's ecosystem value from 2022 to 2024 is $76 billion, while the global average is $20.4 billion. Startup Genome also credits Philly's sector-specific niches for helping it top the charts. Life sciences was cited as a top industry in the region. Startup Genome called out the $30 million dedicated to the sector in the Pennsylvania governor's proposed 2025 to 2026 budget, plus huge raises, like gene therapy company Latus Bio's $54 million round, as reasons for its top performance. As the home of the first FDA-approved cell and gene therapies, Philadelphia is already well-known for its life sciences wins. However, the past six months have challenged that reputation, as the city's gene therapy darling, Spark Therapeutics, recently faced restructuring and layoffs. Analysts at the time agreed, though, that one company-specific setback doesn't undermine what the scene has accomplished (or the millions that continue to be raised). Startup Genome also mentioned AI and big data and robotics and advanced manufacturing as strong sub-sectors in Philly. The report specifically cited big deals like Sojo Industries' $10 million Series A raise last summer and Ghost Robotics' $240 million acquisition by South Korean defense tech company LIG Nex 1. Diverse talent, support from entrepreneurship-focused organizations and collaboration are all reasons startups should consider settling down in the city, according to the report. Startup Genome also highlighted key stakeholders like 1Philadelphia, Comcast NBCUniversal LIFT Labs, Philadelphia Alliance for Capital and Technologies, Philly Startup Leaders (which recently rebranded to Startup Leaders) and Independence Health Group. A tough time for VC, but billions still flow into Philly Philadelphia is also beating out other regions in cash flow. Total VC funding for the city over the last five years is $24 billion, while the global average over the same time period is $5.2 billion. 2024 saw $3.3 billion in venture capital invested over 444 deals, a 37.5% increase from the previous year, the report said. One of the area's strengths is funding for early-stage companies, which aligns with the report's findings of $3.4 billion in early-stage funding from 2022 to 2024. 'At the end of the day, the money will follow the best companies,' Wilson said. 'It's just about getting them ready and plugged in to prepare for that.' Philadelphia faced a hard quarter for venture capital deal flow in Q1 of this year. Local organizations like the ones Startup Genome shouted out are trying to build connections to keep up the momentum. Ben Franklin Technology Partners' GO PA Fund is providing capital to local companies, including $2 million into medtech company Rimsys' $5 million round, per the report. Plus, the Science Center's Capital Readiness Program helps startups prepare to raise capital and brings companies from outside the region in. The Science Center facilitates introductions to potential partners and clients, while also showing off what Philly has to offer with the goal of getting companies to stay, Wilson said. Investments at the state level are also shining a light on Pennsylvania as a whole. Earlier this week, Amazon announced a $20 billion investment in AI across the state, including plans to build a data center in Bucks County. A sign of 'legitimacy, momentum and opportunity' Startup Genome's rankings don't define a startup environment forever; rather, they are a tool for future strategy and decision making, according to Stephan Kuester, managing partner at Startup Genome. Philly's recent jump can provide it with insights on how to sustain the upward trajectory. Higher rankings are often a sign of 'legitimacy, momentum and opportunity,' creating more attention for the market and leading to more opportunities, Kuester said. A low ranking can be a sign to leaders to take action and address gaps. 'Whether an ecosystem rises or falls, the ranking is most valuable when used not as a scoreboard, but as a diagnostic tool,' Kuester said. 'Movement in the rankings should spur collaborative analysis across the ecosystem to understand root causes and adjust course accordingly.' Philadelphia's high ranking will hopefully draw more startup leaders into the scene, Wilson said. Being No. 13 in the world presents an opportunity to connect the dots between investment, job creation and actual human impact happening in the region. 'It's been exciting to bring people into the ecosystem and see them experience that,' Wilson said. 'If we can do that, and we can really demonstrate how we help innovation move from an idea to impact.'

Technical.ly

10-05-2025

• Technical.ly

Regulatory Considerations for AI in MedTech

Event Description As artificial intelligence continues to revolutionize the medical technology industry, navigating the evolving regulatory landscape is crucial for success. This webinar will provide insights into key regulatory considerations for AI-driven medical devices, including FDA requirements, risk assessment, validation strategies, and emerging global regulatory trends. Join Jennifer Palinchik and Fehmida Kapadia as they discuss best practices for bringing AI-powered MedTech innovations to market while ensuring safety, efficacy, and compliance. Whether you're a startup, an established MedTech company, or a regulatory professional, this session will equip you with the knowledge to navigate regulatory challenges effectively.

Technical.ly

09-05-2025

• Technical.ly

Spark layoffs won't derail Philadelphia's biotech surge, city official says

Philly's life sciences sector is strategizing to remain at the forefront, despite recent shakeups at cell and gene therapy pioneer Spark Therapeutics. Turmoil at one big company doesn't necessarily indicate the end of a sector's strength, according to Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce. While acknowledging the negative impact of job losses caused by the layoffs at Spark, Grant said she's still optimistic about the industry at large. 'People in these situations, they know how to pivot the innovation that they've created thus far,' Grant told reporter Sarah Huffman on Speaking, our monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. '[They] will help gene therapy and life sciences to move forward.' Earlier this year, Spark's parent company Roche announced a restructuring of the organization and 300 layoffs at its Philadelphia office. The abrupt shift — following Spark's major success story, from Penn spinout to the era's largest VC-backed exit — caused a moment of reflection for the cell and gene therapy scene. From Grant's perspective, it's been a time to recognize the moral issues at stake and the ecosystem's role in supporting these expensive endeavors. 'As these therapies come about that can actually cure people, and they don't have to continue to take drugs down the line, I think it takes all of us to get involved,' Grant said. Hopefully, jobs come with that. As a global company, Grant said Roche has the opportunity to bring more production jobs to Philadelphia. Those types of roles aren't just for scientists with advanced degrees. There are also training programs for 'aseptic techniques,' or keeping an area sterile, and biomanufacturing in the lab at local organizations like the Wistar Institute and the Skills Initiative. 'The research that's continuing,' Grant said, 'is how to make these treatments less expensive and how to manufacture them so that they are more affordable.'